Swiss National Bank increased its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 8.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,686,899 shares of the company’s stock after buying an additional 298,600 shares during the period. Swiss National Bank owned about 0.36% of Teva Pharmaceutical Industries worth $89,665,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Global X Management Co. LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at about $123,000. Sheaff Brock Investment Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at about $177,000. Financial Advisory Service Inc. purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at about $188,000. ETRADE Capital Management LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at about $188,000. Finally, Wealthstreet Investment Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the second quarter valued at about $200,000. Hedge funds and other institutional investors own 65.50% of the company’s stock.

Shares of NYSE TEVA opened at $23.02 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.03 and a quick ratio of 0.69. The stock has a market capitalization of $24.92 billion, a price-to-earnings ratio of 6.96, a price-to-earnings-growth ratio of 3.06 and a beta of 0.72. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.14. The business had revenue of $4.70 billion during the quarter, compared to the consensus estimate of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The company’s quarterly revenue was down 17.8% on a year-over-year basis. During the same quarter last year, the company earned $1.02 earnings per share. equities analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.67 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, EVP Iris Beck Codner sold 4,165 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the sale, the executive vice president now owns 8,290 shares of the company’s stock, valued at $188,183. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Sven Dethlefs bought 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 3rd. The shares were purchased at an average cost of $21.92 per share, with a total value of $43,840.00. Following the acquisition, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at $141,274.40. The disclosure for this purchase can be found here. 0.43% of the stock is currently owned by company insiders.

Several equities analysts have issued reports on the company. Mizuho reiterated a “buy” rating and issued a $28.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. Wells Fargo & Co set a $23.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Royal Bank of Canada reiterated a “hold” rating and issued a $19.00 target price on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 31st. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday, May 9th. Finally, Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Nine equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $20.45.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.